Literature DB >> 16258759

[Efficacy and tolerability of topical foscarnet sodium in treatment of herpes labialis. Results of post-marketing surveillance].

G Gross1, D Braun.   

Abstract

BACKGROUND AND
OBJECTIVE: Aim of this post-marketing surveillance study was to generate further data on efficacy and tolerability of foscarnet sodium cream 2% in patients with recurrent herpes labialis in daily routine practice. DESIGN AND METHODS: 90 outpatients with recurrent herpes labialis were instructed to apply the antiviral cream to the lesions according to package insert for up to 10 days. Symptoms were recorded before beginning of treatment, after three days, and at the end of treatment.
RESULTS: Paresthesia and swelling as well as the number of vesicles were reduced after three days of observation, and were improved by about 90% at the end of treatment. Erosions and crust formation also improved markedly. Efficacy as well as tolerability were evaluated as positive by the majority of physicians and patients. No adverse reactions were reported.
CONCLUSIONS: Foscarnet sodium 2% cream is an effective and safe medication for the treatment of recurrent labial herpes in daily routine practice of dermatologists.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16258759     DOI: 10.1007/s00105-005-1041-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  17 in total

1.  Effect of foscarnet cream on experimental UV radiation-induced herpes labialis.

Authors:  D I Bernstein; C J Schleupner; T G Evans; D A Blumberg; Y Bryson; K Grafford; P Broberg; S Martin-Munley; S L Spruance
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

2.  Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study.

Authors:  D Lawee; D Rosenthal; F Y Aoki; J Portnoy
Journal:  CMAJ       Date:  1988-02-15       Impact factor: 8.262

3.  Cross-sectional study of recurrent herpes labialis. Prevalence and risk factors.

Authors:  T B Young; E B Rimm; D J D'Alessio
Journal:  Am J Epidemiol       Date:  1988-03       Impact factor: 4.897

Review 4.  Herpes simplex virus infections.

Authors:  R J Whitley; B Roizman
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

Review 5.  Recent developments in herpesvirus therapy.

Authors:  L Naesens; E De Clercq
Journal:  Herpes       Date:  2001-03

6.  Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents.

Authors:  J A Embil; R G Stephens; F R Manuel
Journal:  Can Med Assoc J       Date:  1975-10-04       Impact factor: 8.262

7.  Topical treatment of recurrent genital herpes infections with foscarnet.

Authors:  J Wallin; J O Lernestedt; S Ogenstad; E Lycke
Journal:  Scand J Infect Dis       Date:  1985

8.  Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs.

Authors:  S Alenius; M Berg; F Broberg; K Eklind; B Lindborg; B Oberg
Journal:  J Infect Dis       Date:  1982-04       Impact factor: 5.226

9.  Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.

Authors:  S E Barton; P E Munday; G R Kinghorn; W I van der Meijden; E Stolz; A Notowicz; S Rashid; J L Schuller; A J Essex-Cater; M H Kuijpers
Journal:  Genitourin Med       Date:  1986-08

10.  Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial.

Authors:  S L Sacks; J Portnoy; D Lawee; W Schlech; F Y Aoki; D L Tyrrell; M Poisson; C Bright; J Kaluski
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.